ClinicalTrials.gg
TerminatedNCT01692002Updated Jun 18, 2025Results posted

Oral Propionate to Treat and Prevent Diabetes

An interventional study of Sodium propionate and Sodium Chloride in Diabetes Mellitus, sponsored by Imperial College London. Terminated at 3 sites in United Kingdom. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-18.

Sponsored by Imperial College London · Not applicable, Interventional, and Prevention

How we know

Why this study was terminated
The person who was running the study never completed it, as the study never reached the target recruitment levels.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
6
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies in Diabetes Mellitus by Imperial College London — 2 open to participants now, 4 under way, none of them phase 3. Diabetes Mellitus · Imperial College London.

Enrollment
14th of 15
6 · median 26
Started
2013
with 2 others
No phase
11 of 22
2 open now
Registered
6th of 22
by date

Among the 22 studies in Diabetes Mellitus by Imperial College London, this one is the 14th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2013, is one of 11 with no phase, and was the 6th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

2 of the 22 studies in Diabetes Mellitus by Imperial College London are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Diabetes Mellitus by Imperial College London, or all of them as a file.
02

Study summary

The aim of these studies is to firstly determine the pharmacokinetic profile of orally administered enteric coated sodium propionate. Subsequently, the most efficacious dose at improving glucose tolerance following an oral glucose challenge will be determined. The investigators will then determine the mechanism of action of propionate, whether it acts by altering beta cell function directly or by augmenting the incretin effect or both

Read the detailed description

The NHS spends £1M per hour, 10% of its yearly budget, treating diabetes. In the UK cases of diabetes are expected to top 4 million by 2025. There is an urgent need for new therapies. The short chain fatty acid propionate is a natural substance produced by digestion of fermentable carbohydrates. Preclinical and early human data demonstrate it improves pancreatic function and glucose control. The investigators aim to conduct proof of principle studies to determine if oral delivery of propionate improves glucose control in patients at risk of developing diabetes.

03

Conditions studied

  • Diabetes Mellitus

Browse trials for

Keywords

  • Diabetes Mellitus
  • Propionate
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

Study 1: Healthy men and women aged between 18 and 70 years with between 20-25 kg/m2 and with normal fasting blood glucose (below5.5mmol/l and less than 5.7% will be eligible to volunteer.

Study 2: As for Study 1. Study 3: Cohort 1: Volunteers aged between 30 to 70 with a BMI between 25-35 kg/m2 who do not have impaired fasting glucose and have HbA1c below 5.7%.

Cohort 2: Volunteers aged between 30 to 70 years with a BMI between 25-35 kg/m2 who have impaired fasting glucose (between 5.5-7mmol/l) and HbA1C between 5.7% and 6.5%,

  • Exclusion Criteria:• Type 1 or Type 2 Diabetes

    • Gained or lost ≥ 3kg weight in the past three months
    • Taken prescription medicines having an impact on metabolism, appetite regulation, glucose homeostasis and hormonal regulation
    • Taken any dietary supplements in the last 6 months
    • Any chronic illness
    • Cardiovascular disease
    • Excess alcohol intake
    • Current smokers
    • Any gastrointestinal disorder e.g. Crohn's disease, coeliac disease or irritable bowel syndrome
    • A history of drug or alcohol abuse in the last 2 years
    • Pregnancy (all women of child bearing age will undergo a pregnancy test).
    • Pancreatitis
    • Use of medications likely to interfere with glucose metabolism, appetite regulation, hormonal balance.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
6 participants (actual)

Study arms

  • Placebo comparator
    Sodium chloride pill

    Study 1: pharmacokinetics Study2: Oral glucose tolerance test Study 3: intravenous glucose tolerance test

    Dietary Supplement: Sodium Chloride · Procedure: Oral glucose tolerance test · Procedure: Intravenous glucose tolerance test.

  • Experimental
    Sodium propionate pill

    Study 1: pharmacokinetics Study2: Oral glucose tolerance test Study 3: intravenous glucose tolerance test

    Dietary Supplement: Sodium propionate · Procedure: Oral glucose tolerance test · Procedure: Intravenous glucose tolerance test.

Interventions

  • Dietary supplementSodium propionate

    Sodium propionate capsule or tablet

  • Dietary supplementSodium Chloride

    Placebo capsule or tablet

  • ProcedureOral glucose tolerance test
  • ProcedureIntravenous glucose tolerance test.
06

What researchers measure

Primary outcomes

  1. Propionate CMax

    Study 1: Peak plasma concentration of propionate. Dose ranging and pharmacokinetic profile of propionate by Mass spectrometry has been measured at -10, 0, 15, 30, 60, 90, 120, 150, 180, 4h, 6h, 8h (the mean below was estimated first per patient (across all the above time points) and then per arm across the 6 patients)

    Time frame: hours (up to 8hrs)

Secondary outcomes

  1. Total Amount of Insulin Stimulated by Propionate Per Unit Time (Incremental Area Under the Curve)

    Study 3: Participants will undergo a frequently sampled oral glucose tolerance test (OGTT) to detect changes in insulin sensitivity and beta cell function. Where maximum insulin increments during a glucose tolerance test will be reported on a scale 0 to 1000 where 0 is the lowest and 1000 is the highest outcome

    Time frame: 10 minutes

  2. Insulinogenic Index (Change in Insulin Divided by the Change in Glucose Over the First 30 Minutes of the Test)

    Study 2: insulinogenic index. Oral glucose tolerance dose finding was measured with commercially available kits (the mean below was estimated per arm across the 6 patients)

    Time frame: 30mins

  3. Insulin Levels in Response to the Absorption of Proprionate (Total Insulin Across All Time Points)

    Plasma insulin has been measured using commercially available kits at -10, 0, 15, 30, 60, 90, 120, 150, 180, 4h, 6h, 8h (the mean below was estimated first per patient (across all the above time points) and then per arm across the 6 patients)

    Time frame: hours (up to 8 hours)

07

Results

Posted Jun 18, 2025

Participant flow

Recruitment started March 2013 and ended August 2016. The study was based at the clinical research facility at Imperial College Health Care Trust but never completed. Only 6 where recriuted and completed. The target was 12

1st Period of the Cross-over Study
Participant flow — 1st Period of the Cross-over Study
MilestoneSodium Chloride PillSodium Propionate Pill
Started33
Completed33
Not completed00
Washout Period
Participant flow — Washout Period
MilestoneSodium Chloride PillSodium Propionate Pill
Started33
Completed33
Not completed00
2nd Period of the Cross-over Study
Participant flow — 2nd Period of the Cross-over Study
MilestoneSodium Chloride PillSodium Propionate Pill
Started33
Completed33
Not completed00

Outcome measures

PrimaryPropionate CMax

Study 1: Peak plasma concentration of propionate. Dose ranging and pharmacokinetic profile of propionate by Mass spectrometry has been measured at -10, 0, 15, 30, 60, 90, 120, 150, 180, 4h, 6h, 8h (the mean below was estimated first per patient (across all the above time points) and then per arm across the 6 patients)

Time frame:
hours (up to 8hrs)
Reported as:
Mean · mmol/l
Propionate CMax
mmol/lSodium Chloride CapsuleSodium Propionate Capsule
Propionate CMax7.2 ± 0.267.79 ± 0.25
SecondaryTotal Amount of Insulin Stimulated by Propionate Per Unit Time (Incremental Area Under the Curve)

Study 3: Participants will undergo a frequently sampled oral glucose tolerance test (OGTT) to detect changes in insulin sensitivity and beta cell function. Where maximum insulin increments during a glucose tolerance test will be reported on a scale 0 to 1000 where 0 is the lowest and 1000 is the highest outcome

Time frame:
10 minutes
Reported as:
Mean · uM/min
Total Amount of Insulin Stimulated by Propionate Per Unit Time (Incremental Area Under the Curve)
uM/minSodium Chloride CapsuleSodium Propionate Capsule
Total Amount of Insulin Stimulated by Propionate Per Unit Time (Incremental Area Under the Curve)677.5 ± 24678 ± 25
SecondaryInsulinogenic Index (Change in Insulin Divided by the Change in Glucose Over the First 30 Minutes of the Test)

Study 2: insulinogenic index. Oral glucose tolerance dose finding was measured with commercially available kits (the mean below was estimated per arm across the 6 patients)

Time frame:
30mins
Reported as:
Mean · index
Insulinogenic Index (Change in Insulin Divided by the Change in Glucose Over the First 30 Minutes of the Test)
indexSodium Chloride CapsuleSodium Propionate Capsule
Insulinogenic Index (Change in Insulin Divided by the Change in Glucose Over the First 30 Minutes of the Test)30.2 ± 1231 ± 12.5
SecondaryInsulin Levels in Response to the Absorption of Proprionate (Total Insulin Across All Time Points)

Plasma insulin has been measured using commercially available kits at -10, 0, 15, 30, 60, 90, 120, 150, 180, 4h, 6h, 8h (the mean below was estimated first per patient (across all the above time points) and then per arm across the 6 patients)

Time frame:
hours (up to 8 hours)
Reported as:
Mean · uM/l
Insulin Levels in Response to the Absorption of Proprionate (Total Insulin Across All Time Points)
uM/lSodium Chloride CapsuleSodium Propionate Capsule
Insulin Levels in Response to the Absorption of Proprionate (Total Insulin Across All Time Points)8142 (6809 to 9737)8316 (7148 to 9674)

Adverse events

Collected over 1 week. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sodium Chloride Pill0/3 (0%)0/3 (0%)0/3 (0%)
Sodium Propionate Pill0/3 (0%)0/3 (0%)0/3 (0%)

Baseline characteristics

only 6 where recriuted and completed

Age, Categorical
Age, Categorical(Participants)Sodium ChlorideSodium PropionateTotal
<=18 years000
Between 18 and 65 years336
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Sodium ChlorideSodium PropionateTotal
Female224
Male112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sodium ChlorideSodium PropionateTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White336
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Sodium ChlorideSodium PropionateTotal
United Kingdom336
Propionate
Propionate(micromol/l)Sodium ChlorideSodium PropionateTotal
Mean0.05 ± 0.050.05 ± 0.050.05 ± 0.05
08

Study locations

3 sites
  • Hammersmith Hospital
    London, UK W12 0NN, United Kingdom
  • Imperial College London
    London, W12 0NN, United Kingdom
  • St John McMichael Centre - Imperial College London
    London, W12 0NN, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2013 to primary completion in Aug 2019, 79 months.

Results were first posted in Jun 2025, 5 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2012
First posted
Sep 25, 2012
StartActual
Jan 2013
Primary completionActual
Aug 2019
CompletionActual
Aug 2019
Results first posted
Jun 18, 2025
Last update
Jun 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01692002
Responsible party
Sponsor
First posted
Sep 25, 2012
Start date
Jan 2013
Primary completion
Aug 2019
Completion
Aug 2019
Results posted
Jun 18, 2025
Last update
Jun 18, 2025

Study contacts

Gavin A Bewick, PhD.
principal investigator · Imperial College London

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium propionate

Start the discussion